Rep. Robert Bresnahan, Jr. Sells Off Shares of Incyte Co. (NASDAQ:INCY)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Incyte Co. (NASDAQ:INCY). In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in Incyte stock on May 15th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Zimmer Biomet (NYSE:ZBH) on 5/15/2025.
• Sold $15,001 – $50,000 in shares of Elevance Health (NYSE:ELV) on 5/15/2025.
• Sold $15,001 – $50,000 in shares of PepsiCo (NASDAQ:PEP) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of WEC Energy Group (NYSE:WEC) on 5/15/2025.
• Purchased $15,001 – $50,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 5/15/2025.
• Purchased $1,001 – $15,000 in shares of Kraft Heinz (NASDAQ:KHC) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Exxon Mobil (NYSE:XOM) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of Danaher (NYSE:DHR) on 5/15/2025.
• Sold $1,001 – $15,000 in shares of International Flavors & Fragrances (NYSE:IFF) on 5/15/2025.

Incyte Stock Performance

Shares of NASDAQ INCY opened at $65.31 on Tuesday. The stock’s fifty day simple moving average is $60.88 and its 200 day simple moving average is $67.28. The stock has a market capitalization of $12.64 billion, a price-to-earnings ratio of 241.90, a PEG ratio of 0.41 and a beta of 0.68. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. Incyte Co. has a 52-week low of $53.56 and a 52-week high of $83.95.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.15. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $996.17 million. Incyte had a return on equity of 0.05% and a net margin of 0.77%. Incyte’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter last year, the company posted $0.64 EPS. As a group, sell-side analysts forecast that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Incyte

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC boosted its stake in shares of Incyte by 92.3% during the 1st quarter. AQR Capital Management LLC now owns 6,736,169 shares of the biopharmaceutical company’s stock worth $405,787,000 after acquiring an additional 3,233,356 shares in the last quarter. Norges Bank acquired a new position in Incyte during the 4th quarter worth $121,890,000. Acadian Asset Management LLC boosted its holdings in Incyte by 65.6% during the first quarter. Acadian Asset Management LLC now owns 2,511,872 shares of the biopharmaceutical company’s stock valued at $152,062,000 after acquiring an additional 994,609 shares during the period. Jacobs Levy Equity Management Inc. grew its position in shares of Incyte by 861.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 891,659 shares of the biopharmaceutical company’s stock valued at $61,587,000 after purchasing an additional 798,877 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Incyte by 581.3% in the first quarter. Victory Capital Management Inc. now owns 813,140 shares of the biopharmaceutical company’s stock worth $49,236,000 after purchasing an additional 693,782 shares during the period. 96.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Barry P. Flannelly sold 19,807 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the transaction, the executive vice president now owns 33,567 shares of the company’s stock, valued at approximately $2,272,150.23. The trade was a 37.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 17.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on INCY. Stifel Nicolaus lifted their target price on shares of Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, February 10th. JMP Securities reiterated a “market perform” rating on shares of Incyte in a research report on Tuesday, February 11th. Truist Financial increased their target price on Incyte from $72.00 to $73.00 and gave the company a “hold” rating in a report on Tuesday, May 27th. Royal Bank of Canada raised their target price on Incyte from $64.00 to $67.00 and gave the stock a “sector perform” rating in a research report on Wednesday, April 30th. Finally, Wall Street Zen raised Incyte from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Incyte currently has a consensus rating of “Hold” and a consensus target price of $73.60.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.